ADC Therapeutics will announce second quarter 2024 financial results on Tuesday, August 6 and host a conference call for investors at 8:30 a.m. ET. https://lnkd.in/e3QxSqNp
ADC Therapeutics
Biotechnologieforschung
Lausanne, Vaud, Switzerland 18.112 Follower:innen
Innovating Science. Inspiring Hope.
Info
ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors. Our CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London and New Jersey. Our highly skilled global team is committed to confronting cancer with the full potential of our science and transforming the treatment paradigm for patients with cancer. For more information, please visit https://www.adctherapeutics.com/.
- Website
-
http://www.adctherapeutics.com
Externer Link zu ADC Therapeutics
- Branche
- Biotechnologieforschung
- Größe
- 201–500 Beschäftigte
- Hauptsitz
- Lausanne, Vaud, Switzerland
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
Orte
-
Primär
Lausanne, Vaud, Switzerland, CH
-
430 Mountain Avenue
Suite #404
New Providence, NJ 94404, US
-
1510 Fashion Island Boulevard
Suite 205
San Mateo, CA 94404, US
-
QMB Innovation Centre, 42 New Road
London, E1 2AX, GB
Beschäftigte von ADC Therapeutics
Updates
-
We’re proud to celebrate the 10-year work anniversaries of four members of #TeamADCT from our UK office! Thank you to Karin Havenith, Charlie B., Simone Sims and Lisa Skelton for your 10 years of service with ADCT and for your continued commitment to our mission to transform the lives of those impacted by #cancer.
-
We’re proud to recognize #TeamADCT members Alison Faid and Marie Linda Thölke, who developed an app to automate PK sample analysis and presented their work at the 2024 EBF Young Scientist Symposium. Thank you for your collaborative effort and innovative contribution to optimize our work to improve the lives of patients with #cancer.
-
Are you in Philadelphia for the 13th Process Development for Highly Potent Drugs Summit? Don't miss Jason Moss, our Head of Chemical Development and Manufacturing, talk about lessons learned during drug-linker development and commercial supply of our CD19-targeted #antibodydrugconjugate. For more information about the presentation, visit: https://lnkd.in/dgpc47-b. #HPAPI
-
That’s a wrap on #EHA2024! Members of #TeamADCT were pleased to attend the European Hematology Association (EHA) 2024 Congress in Madrid and connect with industry peers on the latest scientific developments in #hematology #oncology.
-
TODAY: Our CEO Ameet Mallik will present a company overview at the Jefferies Global Healthcare Conference at 11:30 a.m. ET. Access the #webcast via the Events & Presentations page in the Investors section of our website, ir.adctherapeutics.com. #JefferiesHealthcare
-
At ADC Therapeutics, we aspire to embody our core values of integrity, creativity, accountability, collaboration and urgency in our work. Our Values in Action awards were created to encourage and recognize members of #TeamADCT who live by these values. Congratulations to our Values in Action award winners! ⭐ Lara Montolio Núñez (Creativity) ⭐ Christophe GEX (Collaboration) ⭐ Carol B. (Collaboration) ⭐ Leah Tasca (Accountability) ⭐ Yuan Gao (Yuan G.) (Integrity) ⭐ Alison Faid (Urgency)
-
This Sunday, June 2nd is National Cancer Survivors Day, a day to #CelebrateLife and show support for those who have been touched by #cancer. For #TeamADCT, the potential to transform the lives of patients impacted by cancer motivates us every day. #NCSD2024
-
Our CEO Ameet Mallik will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 11:30 a.m. ET. https://lnkd.in/eH3JcaTw #JefferiesHealthcare
-
We’re thrilled to welcome Marcy Graham to #TeamADCT as our new Investor Relations and Corporate Affairs Officer. Marcy brings over 20 years of investor relations and corporate communications experience within the healthcare industry to ADC Therapeutics. We look forward to leveraging her expertise as we continue progressing our differentiated #antibodydrugconjugates to transform the lives of those impacted by cancer.
Ähnliche Seiten
Finanzierung
Letzte Runde
Kapitalerhöhung nach Börsengang105.000.000,00 $